Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: To report oncologic outcomes of patients undergoing salvage cryotherapy (SCT) for local recurrence of prostate cancer (PCa) and to establish a nadir PSA (nPSA) value that best defines long-term oncologic success.
METHODS: Retrospective study of men who underwent SCT for local recurrence of PCa between 2008 and 2020. SCT was performed in men with biochemical recurrence (BCR), after primary treatment and with biopsy-proven PCa local recurrence. Survival analysis with Kaplan-Meier and Cox models was performed. We determined the optimal cutoff nPSA value after SCT that best classifies patients depending on prognosis.
RESULTS: Seventy-seven men who underwent SCT were included. Survival analysis showed a 5-year biochemical recurrence-free survival (BRFS), androgen deprivation therapy-free survival (AFS), and metastasis-free survival (MFS) after SCT of 48.4%, 62% and 81.3% respectively. On multivariable analysis for perioperative variables associated with BCR, initial ISUP, pre-SCT PSA, pre-SCT prostate volume and post-SCT nPSA emerged as variables associated with BCR. The cutoff analysis revealed an nPSA < 0.5 ng/ml to be the optimal threshold that best defines success after SCT. 5-year BRFS for patients achieving an nPSA < 0.5 vs nPSA ≥ 0.5 was 64% and 9.5% respectively (p < 0.001). 5-year AFS for men with nPSA < 0.5 vs ≥ 0.5 was 81.2% and 12.2% (p < 0.001). Improved 5-year MFS for patients who achieved nPSA < 0.5 was also obtained (89.6% vs 60%, p = 0.003).
CONCLUSION: SCT is a feasible rescue alternative for the local recurrence of PCa. Achieving an nPSA < 0.5 ng/ml after SCT is associated with higher long-term BRFS, AFS and MFS rates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
World journal of urology - 42(2024), 1 vom: 13. März, Seite 133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carbonell, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.77 |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00345-024-04806-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369678184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369678184 | ||
| 003 | DE-627 | ||
| 005 | 20240315234029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00345-024-04806-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369678184 | ||
| 035 | |a (NLM)38478102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carbonell, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: To report oncologic outcomes of patients undergoing salvage cryotherapy (SCT) for local recurrence of prostate cancer (PCa) and to establish a nadir PSA (nPSA) value that best defines long-term oncologic success | ||
| 520 | |a METHODS: Retrospective study of men who underwent SCT for local recurrence of PCa between 2008 and 2020. SCT was performed in men with biochemical recurrence (BCR), after primary treatment and with biopsy-proven PCa local recurrence. Survival analysis with Kaplan-Meier and Cox models was performed. We determined the optimal cutoff nPSA value after SCT that best classifies patients depending on prognosis | ||
| 520 | |a RESULTS: Seventy-seven men who underwent SCT were included. Survival analysis showed a 5-year biochemical recurrence-free survival (BRFS), androgen deprivation therapy-free survival (AFS), and metastasis-free survival (MFS) after SCT of 48.4%, 62% and 81.3% respectively. On multivariable analysis for perioperative variables associated with BCR, initial ISUP, pre-SCT PSA, pre-SCT prostate volume and post-SCT nPSA emerged as variables associated with BCR. The cutoff analysis revealed an nPSA < 0.5 ng/ml to be the optimal threshold that best defines success after SCT. 5-year BRFS for patients achieving an nPSA < 0.5 vs nPSA ≥ 0.5 was 64% and 9.5% respectively (p < 0.001). 5-year AFS for men with nPSA < 0.5 vs ≥ 0.5 was 81.2% and 12.2% (p < 0.001). Improved 5-year MFS for patients who achieved nPSA < 0.5 was also obtained (89.6% vs 60%, p = 0.003) | ||
| 520 | |a CONCLUSION: SCT is a feasible rescue alternative for the local recurrence of PCa. Achieving an nPSA < 0.5 ng/ml after SCT is associated with higher long-term BRFS, AFS and MFS rates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Local recurrence | |
| 650 | 4 | |a Nadir PSA | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Salvage cryotherapy | |
| 650 | 4 | |a Salvage treatment | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Mercader, C |e verfasserin |4 aut | |
| 700 | 1 | |a Sureda, J |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, J |e verfasserin |4 aut | |
| 700 | 1 | |a Gallardo, E |e verfasserin |4 aut | |
| 700 | 1 | |a Feltes, N |e verfasserin |4 aut | |
| 700 | 1 | |a Mases, J |e verfasserin |4 aut | |
| 700 | 1 | |a Valduvieco, I |e verfasserin |4 aut | |
| 700 | 1 | |a Vilaseca, A |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alcaraz, A |e verfasserin |4 aut | |
| 700 | 1 | |a Musquera, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ribal, M J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of urology |d 1988 |g 42(2024), 1 vom: 13. März, Seite 133 |w (DE-627)NLM07484959X |x 1433-8726 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:13 |g month:03 |g pages:133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00345-024-04806-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 13 |c 03 |h 133 | ||